NeuroScience, Inc. has launched NeuroSLP, a medical protocol that tests for potential imbalances in the hormones and neurotransmitters that regulate sleep. This protocol enhances a clinician's ability to make more informed decisions regarding patient care.

The NeuroSLP protocol is a major advance in the way healthcare practitioners approach sleep difficulties. The system combines cutting edge sleep biochemistry information with laboratory testing to help healthcare practitioners pinpoint potential imbalances, and develop more targeted therapeutic regimens for individual patients.

The protocol includes an enhanced non-invasive lab test that measures the key neurotransmitters and hormones in sleep biochemistry. The concentration of melatonin, classically considered the "sleep hormone," is only one of twelve biomarkers in the profile. Other sleep-influencing hormones and neurotransmitters measured include cortisol, y-amino butyric acid (GABA), and serotonin.

Coupled with an array of sleep-promoting interventions with differing modes of action, clinicians can use the protocol to tailor therapies to patients' individual biochemical profiles, potentially increasing positive outcomes and reducing unwanted side-effects. Eileen Wright, MD, of Great Smokies Medical Center in Asheville, North Carolina, stated, "Therapies guided by this testing have changed the lives of many individuals in my practice."

About NeuroScience, Inc:

NeuroScience, Inc., established in 1998, is a research-based medical solutions company committed to improving health through the nervous system by providing novel laboratory assessments in the fields of neurology, endocrinology, and immunology. NeuroScience, Inc.'s, laboratory services through Pharmasan Labs, Inc. have been utilized to assess multiple clinical complaints. NeuroScience, Inc.'s database consists of over 300,000 individual results.

Source: NeuroScience, Inc

Tag Cloud